Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has announced the convening of its 2025 third extraordinary general meeting (EGM) scheduled for December 2, 2025. The meeting will address resolutions concerning related party transactions for 2026 to 2028 and amendments to several governance policies, which could impact the company’s operational and strategic framework.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$86.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates within the pharmaceutical industry, focusing on biopharmaceutical products and services. The company is listed on the Stock Exchange of Hong Kong Limited.
Average Trading Volume: 7,148,101
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.78B
Learn more about 9995 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- Ford Mustang Cobra Jet Fastest Electric Car on the Planet, Ford Stock (NYSE:F) Notches Up
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test